Answers are grounded in this paper and cite their sources.
This is a brief report of a patient who has refractory Myasthenia Gravis, on multiple long-term immunosuppressive therapies and contracted COVID-19 during this 2020 pandemic. She was quarantined for total of 14 days and recovered successfully without any complications (no myasthenia exacerbation or crisis, no COVID-19 related complications), with no changes to her immunosuppressive therapy. Treatment of MG patients with COVID-19 needs to be tailored to individual patient.
No takes yet. Share an insight, caveat, or question.
Ramaswamy et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: